gatifloxacin has been researched along with Drug-Related Side Effects and Adverse Reactions in 6 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess outcome and adverse drug events with a standardised 12-month regimen for MDR-TB among second-line drug naïve patients." | 1.42 | High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. ( Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A, 2015) |
| "Gatifloxacin could cause multi-system and multi-organ ADRs with wide variety of clinical manifestations." | 1.35 | [Analysis of adverse drug reaction of gatifloxacin in Hunan province from Aug. 2003 to Jul. 2007]. ( Deng, S; He, Y; Long, L; Yin, T; Zhang, W, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Tomita, T | 1 |
| Kuaban, C | 1 |
| Noeske, J | 1 |
| Rieder, HL | 1 |
| Aït-Khaled, N | 1 |
| Abena Foe, JL | 1 |
| Trébucq, A | 1 |
| Deng, S | 1 |
| He, Y | 1 |
| Yin, T | 1 |
| Long, L | 1 |
| Zhang, W | 1 |
| Lexchin, J | 1 |
1 review available for gatifloxacin and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
[Research on Insufficient Information for Pharmaceutical Products].
Topics: Animals; Diethylhexyl Phthalate; Drug Information Services; Drug Labeling; Drug-Related Side Effects | 2017 |
5 other studies available for gatifloxacin and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cameroon; Clofazimine; Cohort Studies; Confidence In | 2015 |
[Analysis of adverse drug reaction of gatifloxacin in Hunan province from Aug. 2003 to Jul. 2007].
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Infective | 2009 |
Information about a discontinued drug.
Topics: Adverse Drug Reaction Reporting Systems; Awareness; Canada; Drug Information Services; Drug-Related | 2008 |